Macroaxis: Personalized Investing
Simple Personalized Investing

BAX COV BDX BCR Books Consumer Electronics Rentals 
Benchmark SP 500  1,650   0.91  Index Moved Down -0.06% ...


Processing
Collecting data for COV

Covidien quote and profile

 
 Companies |  Insiders  | Dashboard  
     
65.17
  
STOCK
(0.04)  Macroaxis: -0.06 Down   0.06%  
Year To Date
50.2568.83
Last 1 Month(s)
61.9666.55
Trading Day 
64.5765.62
May 25 2013 

Diversification Suggestion

Use Covidien to protect against small markets fluctuations. The stock experiences normal downward trend and little activity
Analyze Covidien plc Trend or Check current 30 days Covidien correlation with market (S&P 500)
1 Month Beta 1.11  
Highest Price:  
Lowest Price:  
66.55  
61.96  
May 14 2013 
April 26 2013 
Covidien returns are very sensitive to returns on the market. As market goes up or down, Covidien is expected to follow.
Covidien plc llmost one BetaCovidien plc Beta Legend
COV United States NYSE
Covidien plc
Healthcare
Medical Instruments and Supplies
Benchmark S&P 500
http://www.covidien.com
Contact Number: 353 1 438 1700
Currency: USD - US Dollar
Traded on New York Stock Exchange
    
Current Valuation34.34 B
Shares Outstanding470.47 M
Number of Shares Shorted4.07 M
Revenue12.17 B
 United States Nasdaq   0.97 % Macroaxis: 0.97 Moved Up  
 
 United States Russel   0.00 % No Change  
 thisRed COV COV agains markets  0.06 % Macroaxis: 0.06 Moved Down  
 
 United States SP 500   0.06 % Macroaxis: 0.06 Moved Down  
 
 United States NYSE   0.25 % Macroaxis: 0.25 Moved Down  
 
Compare to Competition Get Alpha   Get Advice

Covidien Leadership

Jose Almeida Chairman, CEO and Pres
Kevin DaSilva Vice President Group Financial Officer
Richard Brown Vice President Chief Accounting Officer, Corporate Controller
Mark Trudeau Sr. VP and President of Pharmaceuticals Segment

Covidien Price and Market Media

The median price of Covidien for the period between Thu, Apr 25, 2013 and Sat, May 25, 2013 is 65.54 with a coefficient of variation of 1.82. The daily time series for the period is distributed with a sample standard deviation of 1.18, arithmetic mean of 65.15, and mean deviation of 0.89. The Stock received substential amount of media coverage during this period.
Covidien         SP 500
Price Growth (%)
 
1
Covidien plc Reports Net Plunges 12 On Charges Sales Up ...04/30/2013Macroaxis: News
2
Covidien plc Given Neutral Rating at Zacks05/02/2013Macroaxis: News
3
Covidien plc 2013 GuidanceUpdate Call May 06 201305/07/2013Macroaxis: Seeking Alpha News
4
Covidien plc Price Target Increased to 72.00 by Analysts at ...05/09/2013Macroaxis: News
5
COVIDIEN PLC Covidien Announces Pricing of 750 Million Senio...05/14/2013Macroaxis: News
6
COVIDIEN PLC Covidien Receives FDA 510 Clearance for Nellcor...05/21/2013Macroaxis: News
7
COVIDIEN PLC Covidien Announces Clinical Trial Data Showing ...05/23/2013Macroaxis: News

Covidien Summary

Covidien plc [COV] is traded on New York Stock Exchange in USA. It is located in Dublin, and employs 43,400 people. The company currently falls under 'Large-Cap' category with total capitalization of 30.7 B. Covidien plc runs under Healthcare sector within Medical Instruments and Supplies industry. This company has 470.47 M outstanding shares of which 4.07 M shares are currently shorted by investors with about 1.0 days to cover shorted positions.
Covidien plc develops, manufactures, and sells healthcare solutions for use in clinical and home settings worldwide. more
Past Market
Over 30
Days
0
Out Of
100
 
Chance of
Less
Than
16 %
 
Follow Covidien with Macroaxis syndicated feed, custom widget, or your favorite custom stock ticker
Add To Reader
 
Add Covidien to your reader
 

Covidien Research Report

Covidien vs. Baxter

Correlation analysis and fundamentals comparison between Covidien plc and Baxter International

Covidien Executives

Charles Dockendorff CFO and Executive VP

Covidien Directors

Timothy Donahue Lead Independent Director
Joseph Zaccagnino Independent Director
Randall Hogan Independent Director
Dennis Reilley Independent Director
Joy Amundson Director

Covidien Management

John Masterson Sr. VP and General Counsel

Covidien Fundamentals

Earnings Per Share vs Total Debt
One Year High vs Price to Earning
Earnings Per Share vs Revenue
Current Valuation vs Price to Earning

Covidien vs Competition

Covidien vs. Baxter International Inc
Covidien vs. Becton Dickinson and Company
Covidien vs. CR Bard Inc
Covidien vs. CareFusion Corporation
Covidien vs. DENTSPLY International Inc
Covidien vs. The Cooper Companies Inc
Covidien vs. Mindray Medical International Limited
Covidien vs. Teleflex Incorporated
Covidien vs. West Pharmaceutical Services Inc

Covidien May 25 2013 Opportunity Range

Downside Deviation2.41
Information Ratio(0.16)
Maximum Drawdown6.64
Value At Risk(1.13)
Potential Upside1.23

 
Analytics
Risk Adjusted Returns Landscape
Live Efficient Frontier
Market Correlation Analysis
Watchlist Analysis
Financial Content
Portfolio Estimation and Projections
Portfolio Theme Builder
 
 
Research Modules
Equities Backtesting Analysis
Instant Retirement Optimizer
Cross-portfolio RSS and Mobile Access
Company, fund, and ETF Directory
Financial Advisor Directory
Insider and Manager Directory
Wealth Management
 Gadgets, Widgets, and Apps          
  
 
Services And Technology
Frequently Asked Questions
Quick Product Tour
Product Technology Overview
Solution Methodology
Plans and Pricing
 
Free Investor Tools
World Market Correlations
Instant Equity Comparator
Watchlist Analysis
Position Suggestions
Equity Alpha Analysis
 
About Us
About Macroaxis
Contact Us
Product Terms Of Use
Service Privacy Policy
Advertising Opportunities
Content

Thanks for checking out Macroaxis

Tell us what you like and what you don't like. We promise we'll not only listen but write you back

Contact Us
Macroaxis is user-driven community of investors. We appreciate any feedback or comment you can provide. Please fill out our quick survey to help us provide your with a better service and user experience

Fill Out Quick Survey
Most of the functionality on our site is free to use. However we do provide premium service to sophisticated investors. Our premium subscription will give you unprecedented capabilities to optimize your portfolios using robust financial analysis toolkit, fast mean-variance optimization engine, and proven portfolio theory

Go Premium